Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2−, node-positive, high-risk early breast cancer (EBC). 2024 ASCO Annual Meeting II; LBA507 - Loi, S; Johnston, SRD; Arteaga, CL (J Clin Oncol, 2024)